EyePoint Pharmaceuticals, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
9.79
-0.24 (-2.39%)
At close: Jul 29, 2025, 4:00 PM
9.85
+0.06 (0.61%)
After-hours: Jul 29, 2025, 4:00 PM EDT

Company Description

EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.

The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.

Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME).

The company’s pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases.

The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018.

EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

EyePoint Pharmaceuticals, Inc.
EyePoint Pharmaceuticals logo
CountryUnited States
Founded1987
IPO DateJan 27, 2005
IndustryBiotechnology
SectorHealthcare
Employees165
CEOJay Duker

Contact Details

Address:
480 Pleasant Street, Suite A-210
Watertown, Massachusetts 02472
United States
Phone617 926 5000
Websiteeyepointpharma.com

Stock Details

Ticker SymbolEYPT
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001314102
CUSIP Number30233G209
ISIN NumberUS30233G2093
Employer ID26-2774444
SIC Code3826

Key Executives

NamePosition
Dr. Anna KluczewskaChief Executive Officer of AION Diagnostics Ltd, President of AION Diagnostics Ltd and Director of AION Diagnostics Ltd
Dr. Jay S. Duker M.D.President, Chief Executive Officer and Director
George O. Elston CPAExecutive Vice President and Chief Financial Officer
Dr. Ramiro Ribeiro M.D., Ph.D.Chief Medical Officer
Dr. Marcia Sellos-Moura Ph.D.Chief Scientific Officer
Ron I. Honig Esq.Chief Legal Officer and Company Secretary
Jennifer LeonardChief People Officer and Senior Vice President of IT
David Scott Jones M.A.Senior Vice President and Chief Commercial Officer
Isabelle LefebvreChief Regulatory Officer
Michael J. MaciocioChief Manufacturing Officer

Latest SEC Filings

DateTypeTitle
Jul 29, 20258-KCurrent Report
Jul 8, 2025SCHEDULE 13G/AFiling
Jun 20, 20258-KCurrent Report
May 27, 20258-KCurrent Report
May 9, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
May 8, 202510-QQuarterly Report
May 7, 20258-KCurrent Report
Apr 28, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 28, 2025DEF 14AOther definitive proxy statements
Mar 6, 202510-KAnnual Report